IL22 and fatty liver disease: Moreover, treatment with recombinant murine IL-22 (rmIL-22) was proven to decrease lipid content and hepatic steatosis in ob/ob mice fed a HFD via reducing the expression of genes associated with lipogenesis (such as sterol regulatory element-binding protein-1c (SREBP-1c), fatty acid synthase (FAS), ATP citrate lyase (ACLY) and elongation of very-long-chain fatty acids protein 6 (ELOVL6)), and reduces expression of gluconeogenesis-related enzymes (such as phosphoenolpyruvate carboxykinase (PEPCK)) in murine [26,27].